Sialylation-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in uterine corpus endometrial carcinoma-Reference-Cited by-同舟云学术

Sialylation-associated long non-coding RNA signature predicts the prognosis, tumor microenvironment, and immunotherapy and chemotherapy options in uterine corpus endometrial carcinoma

Published:2024-09-11 Issue:1 Volume:24 Page:
ISSN:1475-2867
Container-title:Cancer Cell International
language:en
Short-container-title:Cancer Cell Int

Author:

Chen Jun,Wu Tingting,Yang Yongwen

Funder

Hunan Provincial Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12935-024-03486-z.pdf

Reference43 articles.

1. Mahdi H, Ray-Coquard I, Lorusso D, Mirza MR, Monk BJ, Slomovitz B. Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: when is hormonal-based therapy the preferred option? Int J Gynecol cancer: Official J Int Gynecol Cancer Soc. 2023;33(11):1675–81.

2. Zhu L, Zhu Y, Li F, Meng Y, Wang H, Xu W, Luo J, Wang X, Feng L, Jin H. RNautophagic regulation of DNMT3a-dependent DNA methylation by Linc00942 enhances chemoresistance in gastric cancer. Clin Translational Med. 2023;13(7):e1337.

3. Cobb LP, Siamakpour-Reihani S, Zhang D, Qin X, Owzar K, Zhou C, Conrads TP, Maxwell GL, Darcy KM, Bateman NW, et al. Obesity and altered angiogenic-related gene expression in endometrial cancer. Gynecol Oncol. 2021;163(2):320–6.

4. Zou Y, Turashvili G, Soslow RA, Park KJ, Croce S, McCluggage WG, Stewart CJR, Oda Y, Oliva E, Young RH, et al. High-grade transformation of low-grade endometrial stromal sarcomas lacking YWHAE and BCOR genetic abnormalities. Mod Pathology: Official J United States Can Acad Pathol Inc. 2020;33(9):1861–70.

5. Boelaars K, Goossens-Kruijssen L, Wang D, de Winde CM, Rodriguez E, Lindijer D, Springer B, van der Haar Àvila I, de Haas A, Wehry L et al. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer. J Immunother Cancer 2023, 11(11).